Autoimmunity in the Pathogenesis of AF
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03498729 |
Recruitment Status :
Recruiting
First Posted : April 17, 2018
Last Update Posted : July 10, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Atrial Fibrillation | Other: Peripheral Blood Sample |
Study Type : | Observational |
Estimated Enrollment : | 240 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | The Role of Autoimmune Mechanisms in the Pathogenesis of Atrial Fibrillation |
Actual Study Start Date : | March 5, 2018 |
Estimated Primary Completion Date : | December 31, 2021 |
Estimated Study Completion Date : | December 31, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Persistent AF |
Other: Peripheral Blood Sample
30mL peripheral whole blood sample |
Paroxysmal AF |
Other: Peripheral Blood Sample
30mL peripheral whole blood sample |
Psoriasis |
Other: Peripheral Blood Sample
30mL peripheral whole blood sample |
Healthy Controls |
Other: Peripheral Blood Sample
30mL peripheral whole blood sample |
- Cytokines Levels [ Time Frame: through study completion, approximately 3 years. ]Cytokine Profiles

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Cases: AF (Persistent, paroxysmal AF)
- Controls 1: (No prior history of AF or inflammatory or autoimmune diseases)
- Controls 2: (biopsy proven Psoriasis)
Exclusion Criteria:
- Clinically apparent acute infections over the past 4 weeks
- Chronic infections
- Recent malignancies
- Recent Radiation or chemotherapy
- Chronic kidney disease (≥ stage 2)
- Organ transplantation
- History of chronic liver disease
- Major surgery or invasive procedure in the past 6 months
- Internal prosthesis
- Receiving immunosuppressive therapy
- Known rheumatologic diseases (except for the participants with psoriasis)
- Females who are known to be pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03498729
Contact: Rowlens M. Melduni, M.D., M.P.H. | (507) 538-0325 | Melduni.Rowlens@mayo.edu | |
Contact: Hannah Frost | (507) 293-2762 | Frost.Hannah@mayo.edu |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Rowlens M. Melduni, M.D., M.P.H. 507-538-0325 Melduni.Rowlens@mayo.edu |
Principal Investigator: | Rowlens M. Melduni, MD | Mayo Clinic |
Responsible Party: | Rowlens M. Melduni, Consultant, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT03498729 |
Other Study ID Numbers: |
16-005678 1K01HL135288-01 ( U.S. NIH Grant/Contract ) |
First Posted: | April 17, 2018 Key Record Dates |
Last Update Posted: | July 10, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Autoimmune Diseases |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |